Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
about
Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments.Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence
P2860
Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cost-effectiveness analysis of ...... genotype 3 infected patients.
@en
type
label
Cost-effectiveness analysis of ...... genotype 3 infected patients.
@en
prefLabel
Cost-effectiveness analysis of ...... genotype 3 infected patients.
@en
P2093
P2860
P1476
Cost-effectiveness analysis of ...... genotype 3 infected patients.
@en
P2093
Aisling O'Leary
Javier Mar
Ramón San Miguel
Róisín Adams
Vicente Gimeno-Ballester
P2860
P356
10.1080/17474124.2016.1222271
P577
2016-08-08T00:00:00Z